RxDoctor Payments Data

van Hoang, MD

Pulmonary Disease · Houston, TXNPI 1124311998

Payments from drug & device makers

$670in general payments, 2019–2025

Across 29 payments — averaging $23.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$200
  • Blueprint Medicines Corporation$92
  • Sunovion Pharmaceuticals Inc.$57
  • Sanofi$55
  • Regeneron Healthcare Solutions, Inc.$40
  • Genentech USA, Inc.$39
  • plus $186 from 9 others

What the payments were for

  • Food & beverage$47070%
  • Education$20030%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$670 in reported general payments places this provider in the 30th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$38,975
Medicare patients
152
Services billed
347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$94,264
Spiriva RespimatTiotropium Bromide56$65,829
Breztri AerosphereBudesonide/Glycopyr/Formoterol69$61,394
Stiolto RespimatTiotropium Br/Olodaterol Hcl69$52,836
Advair HfaFluticasone Propion/Salmeterol37$31,778
Breo ElliptaFluticasone/Vilanterol30$20,617
SymbicortBudesonide/Formoterol Fumarate29$15,932
Incruse ElliptaUmeclidinium Bromide15$10,876
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$10,053
Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol16$7,903
Atrovent HfaIpratropium Bromide14$6,837
Fluticasone-SalmeterolFluticasone Propion/Salmeterol35$6,497
Qvar RedihalerBeclomethasone Dipropionate21$6,379
Albuterol Sulfate HfaAlbuterol Sulfate174$5,024
Fluticasone Propionate HfaFluticasone Propionate18$4,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$15$135,810135 claims
AstraZenecaBreztri Aerosphere, Symbicort$36$77,32698 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →